

WE CLAIM:

1. An antibody that binds human IL-33, comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2, and HCDR3, and wherein the amino acid sequence of LCDR1 is SEQ ID NO: 16, the amino acid sequence of LCDR2 is SEQ ID NO: 17, the amino acid sequence of LCDR3 is SEQ ID NO: 18, the amino acid sequence of HCDR1 is SEQ ID NO: 13, the amino acid sequence of HCDR2 is SEQ ID NO: 14, and the amino acid sequence of HCDR3 is SEQ ID NO: 15, and wherein:
 - a) Xaa at position 6 of SEQ ID NO: 13 is Ser, Xaa at position 2 of SEQ ID NO: 15 is Leu, Xaa at position 6 of SEQ ID NO: 17 is Ala, and Xaa at position 6 of SEQ ID NO: 18 is Ser;
 - b) Xaa at position 6 of SEQ ID NO: 13 is Phe, Xaa at position 2 of SEQ ID NO: 15 is Leu, Xaa at position 6 of SEQ ID NO: 17 is Leu, and Xaa at position 6 of SEQ ID NO: 18 is Pro; or
 - c) Xaa at position 6 of SEQ ID NO: 13 is Phe, Xaa at position 2 of SEQ ID NO: 15 is Ile, Xaa at position 6 of SEQ ID NO: 17 is Leu, and Xaa at position 6 of SEQ ID NO: 18 is Pro.
2. The antibody of Claim 1, wherein:
 - a. Xaa at position 6 of SEQ ID NO: 13 is Ser;
 - b. Xaa at position 2 of SEQ ID NO: 15 is Leu;
 - c. Xaa at position 6 of SEQ ID NO: 17 is Ala; and
 - d. Xaa at position 6 of SEQ ID NO: 18 is Ser.
3. The antibody of Claim 1, wherein:
 - a. Xaa at position 6 of SEQ ID NO: 13 is Phe;
 - b. Xaa at position 2 of SEQ ID NO: 15 is Leu;
 - c. Xaa at position 6 of SEQ ID NO: 17 is Leu; and
 - d. Xaa at position 6 of SEQ ID NO: 18 is Pro.
4. The antibody of Claim 1, wherein:
 - a. Xaa at position 6 of SEQ ID NO: 13 is Phe;
 - b. Xaa at position 2 of SEQ ID NO: 15 is Ile;
 - c. Xaa at position 6 of SEQ ID NO: 17 is Leu; and

- d. Xaa at position 6 of SEQ ID NO: 18 is Pro.
5. The antibody of Claim 1, wherein the amino acid sequence of the LCVR is SEQ ID NO: 4, and the amino acid sequence of the HCVR is SEQ ID NO: 3.
 6. The antibody of Claim 1, wherein the amino acid sequence of the LCVR is SEQ ID NO: 8, and the amino acid sequence of the HCVR is SEQ ID NO: 7.
 7. The antibody of Claim 1, wherein the amino acid sequence of the LCVR is SEQ ID NO: 12, and the amino acid sequence of the HCVR is SEQ ID NO: 11.
 8. The antibody of Claim 1, comprising a light chain (LC) and a heavy chain (HC), wherein the amino acid sequence of the LC is SEQ ID NO: 2, and the amino acid sequence of the HC is SEQ ID NO: 1.
 9. The antibody of Claim 1, comprising a LC and a HC, wherein the amino acid sequence of the LC is SEQ ID NO: 6, and the amino acid sequence of the HC is SEQ ID NO: 5.
 10. The antibody of Claim 1, comprising a comprising a LC and a HC, wherein the amino acid sequence of the LC is SEQ ID NO: 10, and the amino acid sequence of the HC is SEQ ID NO: 9.
 11. A pharmaceutical composition comprising the antibody of any one of Claims 1-10, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
 12. The antibody of any one of Claims 1-10 for use in therapy.
 13. The antibody of any one of Claims 1-10 for use in the treatment of one or more allergic disease.

14. The antibody of Claim 13, wherein the allergic disease is atopic dermatitis, asthma, allergic rhinitis, or food allergy.
15. The antibody of Claim 14, wherein the allergic disease is atopic dermatitis.
16. The antibody of any one of Claims 1-10 for use in the treatment of eosinophilic esophagitis, scleroderma/systemic sclerosis, ulcerative colitis, or chronic obstructive pulmonary disease.
17. The antibody of any one of Claims 1-10 for use in the treatment of Crohn's disease.
18. Use of the antibody of any one of Claims 1-10 in the manufacture of a medicament for the treatment of one or more allergic disease.
19. The use of Claim 18, wherein the allergic disease is atopic dermatitis, asthma, allergic rhinitis, or food allergy.
20. The use of Claim 19, wherein the allergic disease is atopic dermatitis.
21. Use of the antibody of any one of Claims 1-10 in the manufacture of a medicament for the treatment of eosinophilic esophagitis, scleroderma/systemic sclerosis, ulcerative colitis, or chronic obstructive pulmonary disease.
22. Use of the antibody of any one of Claims 1-10 in the manufacture of a medicament for the treatment of Crohn's disease.
23. A DNA molecule comprising a polynucleotide sequence encoding a HC having the amino acid sequence of SEQ ID NO: 9, and comprising a polynucleotide sequence encoding a LC having the amino acid sequence of SEQ ID NO: 10.

24. A mammalian cell transformed with the DNA molecule of claim 23, wherein the cell is capable of expressing an antibody comprising a HC given by the amino acid sequence of SEQ ID NO: 9 and a LC given by the amino acid sequence of SEQ ID NO: 10.
25. A process for producing an antibody, which antibody comprises two HCs and two LCs, in which the amino acid sequence of each of the two HCs is given by the amino acid sequence of SEQ ID NO: 9 and the amino acid sequence of each of the two LCs is given by the amino acid sequence of SEQ ID NO: 10, wherein the process comprises:
 - a. cultivating the mammalian cell of claim 24 under conditions such that the antibody expressed, and
 - b. recovering the expressed antibody.